Molecular virology and immunology of HIV infection

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 2, 2002, Pages 189-198

  Chinen, Javier ^a   Shearer, William T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; CD4; Chemokine; Cytokine; HIV; Immunology; Lymphocyte; Monocyte; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; POL PROTEIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; B LYMPHOCYTE; CELLULAR IMMUNITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; IMMUNOLOGY; IMMUNOPATHOGENESIS; MOLECULAR BIOLOGY; MONOCYTE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIROLOGY; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0036677041     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.126226     Document Type: Article

References (124)

1. Update on trends in AIDS incidence, deaths and prevalence - United States
2. Natural history of HIV infection in the era of combination antiretroviral therapy
3. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
4. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection
5. Human immunodeficiency virus and its replication
6. What role does HIV-1 subtype plays in transmission and pathogenesis? An epidemiological perspective
7. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions
8. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
9. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
10. Chemokine receptors: Keys to AIDS pathogenesis
11. The HIV-1 envelope glycoproteins: Fusogens, antigens and immunogens
12. The fusion domain of HIV gp4-1 interacts specifically with heparan sulfate on the T-lymphocyte surface
13. Genotypic and phenotypic characterization of HIV-1 patients with primary infection
14. Co-receptors for HIV-1 entry
15. Coreceptors: Implications for HIV pathogenesis and therapy
16. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates
17. Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals
18. + T lymphocytes using CD8 as a receptor
19. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
20. Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1
21. Locations of anti-AIDS drug binding sites and resistance mutations in the three dimensional structure of HIV-1 reverse transcriptase
22. ABC of AIDS. Antiretroviral drugs
23. Cytoplasmic retention of HIV-1 regulatory protein Vpr by protein-protein interaction with a novel cytoplasmic protein VprBP
24. HIV accessory proteins as therapeutic targets
25. HIV cDNA integration: Molecular biology and inhibitor development
26. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain
27. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
28. Regulatory mechanisms involved in the control of HIV-1 expression
29. Characterization of ribosomal frame-shifting in HIV-1 gag-pol expression
30. The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process
31. CD4 glycoprotein degradation induced by human immunodeficiency virus type Vpu protein requires the function of protoosomes and the ubiquitin-conjugating pathway
32. The human immunodeficiency virus type 1 Vpu protein inhibits NFkappa B activation by interfering with beta TrCP-mediated degradation of 1kappa B
33. Antiviral pressure exerted by HIV-1 specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
34. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
35. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T-cell clones during primary HIV infection
36. gp120-and TNF-alpha induced modulation of human B cell function: Proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression
37. Human immunodeficiency virus infection induces both polyclonal and virus-specific B-cell activation
38. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders
39. HIV disease in children is associated with a selective decrease in CD23 and CD62L B-cells
40. Cell-mediated and humoral immune responses in children infected with human immunodeficiency virus during the first 4 years of life
41. Antibody responses to Hemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection
42. HIV-1 induced phenotypic and functional perturbations of B cells in chronically infected individuals
43. Mapping the Ig superantigen-binding site of HIV gp120
44. Antibody-independent, complement-mediated enhancement of HIV-1-infection by mannosidase I and II inhibitors
45. Complement-mediated enhancement of HIV-1-infection of the monoblastoid cell line U937
46. Soluble CD16 inhibits CR3-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1
47. The supportive role of complement in HIV pathogenesis
48. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1
49. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
50. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 infection syndrome
51. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads
52. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
53. Cellular immune responses to HIV
54. Decline of CD3 T-cell counts by six months of age is associated with rapid disease progression in HIV-1-infected infants
55. Decline in total T-cell count is associated with onset of AIDS, independent of CD4 lymphocyte count: Implications for AIDS pathogenesis
56. Predictive value of quantitative RNA and CD4 lymphocyte count for disease progression and response therapy in HIV-infected children
57. Early and persistent human immunodeficiency virus type-1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection
58. HIV-1-specific CD4+ T-cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
59. Vigorous HIV-1 specific CD4+ T-cell responses associated with control of viremia
60. Lymphocyte proliferative responses to HIV antigens as a potential measure of immune reconstitution in HIV disease
61. T-cell activation in pediatric AIDS pathogenesis: Three-color immunophenotyping
62. CD4 memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children
63. Perturbation of CD4+ and CD8+ T-cell repertories during progression to AIDS and regulation of the CD4+ repertories during antiviral therapy
64. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
65. The dynamics of CD4 T-cell depletion in HIV disease
66. Model of HIV-1 disease prognosis based on virus-induced lymph node homing and homing-induced apoptosis of CD4 lymphocytes
67. The importance of lymphocyte trafficking in regulating blood lymphocyte levels during HIV and SIV infections
68. CCR5 and CXR4 strain of HIV-1 exhibit differential tropism and pathogenesis in vivo
69. HIV-1 induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo
70. DC-SIGN, a dendritic cell specific HIV-1 binding protein that enhances trans-infection of T-cells
71. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
72. Dramatic rise in plasma viremia after CD8+ T-cell depletion in simian immunodeficiency virus-infected macaques
73. Major expansion of CD8 T-cells with a predominant Vb usage during the primary response of HIV
74. Elevated levels of CD38 CD8 T cells add to the prognostic value of low CD4 T cell levels: Results of 6 years of follow up
75. Comparison of CD8+ T-cell subsets in HIV-infected rapid progressor children vs non-rapid progressor children
76. CD8 cell anti HIV activity correlates with the clinical state of the infected individuals
77. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
78. Virus specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
79. Quantitation of HIV-1 specific cytotoxic T-lymphocytes and plasma load of viral RNA
80. Human immunodeficiency virus type-1 specific cytotoxic T lymphocytes (CTL) viral load, and CD4 T-cell loss: Evidence supporting a protective role for CTL in vivo
81. Maintenance of large numbers of virus-specific CD8 T-cells in HIV-infected progressors and non-progressors
82. Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T-lymphocytes can persist at high frequency for proolonged periods in the absence of circulating peripheral CD4+ T cells
83. Association between HIV-specific T helper responses and CTL activities in pediatric AIDS
84. High viral burden in the presence of major HIV-specific CD8+ T-cell expansions: Evidence for impaired CTL effector function
85. HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function
86. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: A review of the literature examining associations with HLA
87. New Class I and Class II HLA alleles strongly associate with opposite patterns of progression to AIDS
88. Influence of combinations of human major histocompatibility complex genes on the course of HIV infection
89. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission
90. Effect of a single amino acid change in MHC Class I molecules in the rate of progression to AIDS
91. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection
92. Differential production of interleukin 10 during human immunodeficiency virus infection
93. Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases
94. Spontaneous cytotoxity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients
95. Impaired interleukin 12 production in human immunodeficiency virus-infected patients
96. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children
97. Clinical progression of HIV infection: Role of NK cells
98. Leukemia inhibitor factor inhibits HIV-1 replication and is upregulated in placenta from nontransmitting women
99. Interleukin-7 and infection itself by human immunodeficiency virus 1 favor virus persistence in mature CD4+CD8-CD3+ thymocytes through sustained induction of bcl-2
100. Relative resistance to HIV-1 infection of CD4 lymphocytes despite multiple high-risk exposures
101. CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection, yet not sustained replication in Th1 and Th2 cells
102. Identification of RANTES, MIP-1alpha, MIP-1beta as the major HIV-1 suppressive factors produced by CD8 T-cells
103. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell line adapted HIV-1
104. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression
105. Protective role of b-chemokines associated with HIV-specific Th responses against perinatal HIV transmission
106. Vaccines for prevention of HIV disease
107. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replication particles
108. Factors associated with slow-disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251
109. Mucosal immunization of cynomolgus macaques with two serotypes of life poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal and cellular immunity
110. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
111. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
112. Cytotoxic T-cell responses to multiple conserved HIV epitopes in HIV resistant prostitutes in Nairobi
113. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen
114. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
115. HIV type 1 vaccine-induced T cells memory and cytotoxic T lymphocyte responses in HIV type-1 uninfected volunteers
116. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk of acquiring HIV type 1 infection
117. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag and Pro in combination with rgp120
118. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interelade cross-reactivity and neutralize several X4-R5-and dual-tropic clade B and C primary isolates
119. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency vires infection in pig-tailed macaques
120. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120w61D derived from dual tropic R5X4 HIV-IACH 320
121. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
122. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta chemokines
123. Genetic immunization: A new era of vaccines and immuno therapeutics
124. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells